Should continuous intravenous (i.v.) heparin be infused via a Y site?
Eisenberg
S
S
Fred Hutchinson Cancer Research Center, Seattle, Wash., USA.
D000925:Anticoagulants / Q000008:administration & dosage*; D003422:Critical Care / Q000379:methods; D006493:Heparin / Q000008:administration & dosage*; D006801:Humans; D007262:Infusions, Intravenous / Q000009:adverse effects / Q000295:instrumentation* / Q000379:methods* / Q000451:nursing
D000925:Anticoagulants; D006493:Heparin